Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In ECPR, where CPR times often range from 30 to 120 minutes, only patients with good circulation during CPR survive, while non-survivors commonly suffer from anoxic brain injury. The selection process during CPR is challenging causing a general survival rate of just 2 out of 10, and the urgent need for better selection criteria has been emphasized. It it crucial to keep cardiac arrest times as short as possible, pre primed-ECMO can facilitate this.
The ECMO treatment and the long CPR times of ECPR can also affect the measurements of the neurologic prognostication guidelines after cardiac arrest, making its validity uncertain in this specific cohort. Further, the long-term neuropsychological follow-up is limited to a few patients, making it uncertain if ECPR gives the survivors good long-term life satisfaction or just a prolonged life.
Our overall aim is to optimize and improve the care pathway for ECPR patients by refining patient selection, assessing pre-primed ECMO, validating neurological prognostication guidelines, and understanding long-term outcomes and challenges faced by survivors.
Specific Aim 1: Evaluating predictors for good neurological outcomes in ECPR and to develop and validate (internally and externally) an evidence-based selection tool for ECPR.
Specific aim 2: To assess the sterility and function of pre-primed ECMO.
Specific aim 3: To evaluate the applicability of current guidelines for neurological prognostication after cardiac arrest in ECPR patients, and to assess the predictive value of individual and combined neurological tests in this specific patient population.
Specific aim 4: To determine the long-term neuropsychological outcomes, identify the problems survivors experience in daily life, and assess life satisfaction - by comprehensive follow-up visits with validated questionnaires and neuropsychology testing up to 12 years after the ECMO-treated cardiac arrest.
Specific aim 1: The aim is to develop an ECPR prognostication tool and validate its performance. In development, possible predictors for good neurological outcomes are prospectively gathered. The predictive ability of the predictors is tested in univariate and multivariable analysis, with the aim of improving patient selection for ECPR. Patients from the Gothenburg ECPR cohort are included in the development study. External validation with the ECMO patients from the Prague OHCA trial, following guidelines for validation studies, will follow, as well as external validation with further patients from Gothenburg.
Specific aim 2: Cardiohelp ECMO circuits are set up dry, followed by wet-priming and used in the ECMO treatments of the centre. The circuits are cultured at ECMO-initiation and the incidence of positive cultures is assessed. The effect of the pre-primed time on ECMO function is also assessed.
Specific aim 3: The predictive ability of the current guideline for neurological prognostication of comatose patients in the ICU after cardiac arrest, from the European Resuscitation Council, is assessed in the ECPR cohort of Gothenburg. The diagnostic performance of individual predictors as well as the total accuracy of the prediction will be assessed.
Specific aim 4: A Long-term (1-12 years) follow-up of the ECPR patients will be performed, to determine the long-term neuropsychological outcomes.
4 A: Life satisfaction after ECPR will be assessed along with anxiety, depression, fatigue, cognitive function, and physical activity. The impact of these factors on life satisfaction will also be evaluated. QUALY will be calculated.
4 B: Long-term neurocognitive function in ECPR patients will be assessed through comprehensive neuropsychological testing, using conventional CPR patients from the TTM2 trial as a control group.
The general ECMO population from 2004 of the center is included as a control group and positive cultures during their ECMO runs are documented.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ECPR patients | Patients that is put om ECMO during cardiac arrest |
| |
| ECMO patients, non-ECPR | Patients that is put on ECMO due to circulatory failure but not cardiac arrest |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest |
|
| Measure | Description | Time Frame |
|---|---|---|
| Modified Rankin scale (MRs) | Assessmenty of cognitive function. 0-6, where 0 is best. | 1 year |
| Performance of ECMO oxygenator function | Oxygenator resistance, and the needed FiO2 and sweep gas flow will be assessed | 0-60 days |
| Positive cultures of pre-primed ECMO circuits | ECMO circuits is pre-primed and cultures taken at the start of ECMO treatment | 0-90 days |
| Predictive ability of ERC neuro prognostication guidelines on ECPR patients | Diagnostic performance and ROC analysis of individual and total ERC predictors on outcome in ECPR | 1 year |
| Life Satisfaction | Visual Analog Scale 1-10. 10 is better. | 1-12 years |
| Euro Qualy - 5 dimension (EQ-5D-5L) VAS | Self-perceived health status. 0-100, where higher is better. | 3 months to 12 years |
| Neurocognitive function | Z-scores of verbal and visual function, episodic and visuospatial memory , processing speed and executive functions. 0 represents standardized population norm and ± 1 represent one standard deviation from that. | 3 months to 12 years after the ECPR-treatment |
| Positive blood Cultures |
| Measure | Description | Time Frame |
|---|---|---|
| MoCA | Assess cognitive function, higher is better. 0-30 where higher is better | 3 months to 12 years after the ECPR treatment |
| Hospital Anxiety and Depression Scale (HADS) | Two sub scales 0-21 which assess anxiety and depression, higer is worse |
| Measure | Description | Time Frame |
|---|---|---|
| Cost | The in hospital cost of the treatment for the patients, in Swedish kronor. | 3 month |
| Short Form -36 (SF-36) | Quality of life. 8 scaled scores from 0-100, where 100 is best. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
ECPR Group: Patients who is put on ECMO during cardiac arrest. ECMO Group: Patients who is put on ECMO with some ongoing circulaiton
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bengt Redfors, MD, PhD | Contact | +46768445402 | bengt.redfors@vgregion.se | |
| Anna Henningsson, MD | Contact | +46700922555 | anna.henningsson@vgregion.se |
| Name | Affiliation | Role |
|---|---|---|
| Bengt Redfors, MD, PhD | The Sahlgrenska Academy ar Sahlgrenska University Hospital, Gorhenburg, Sweden | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sahlgrenska Academy at Sahlgrenska University Hospital | Recruiting | Gothenburg | 41345 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38912528 | Result | Bengtsson D, Jonsson B, Redfors B. Sterility and oxygenator function in pre-primed extracorporeal membrane oxygenation: A prospective clinical study. Resusc Plus. 2024 Jun 5;19:100680. doi: 10.1016/j.resplu.2024.100680. eCollection 2024 Sep. | |
| 39395854 | Result | Redfors B, Byttner A, Bengtsson D, Watson P, Lannemyr L, Lundgren P, Gabel J, Rawshani A, Henningsson A. The Pre-ECPR Score: Developing and Validating a Multivariable Prediction Model for Favorable Neurological Outcomes in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation. J Cardiothorac Vasc Anesth. 2024 Dec;38(12):3018-3028. doi: 10.1053/j.jvca.2024.09.009. Epub 2024 Sep 17. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006323 | Heart Arrest |
| D020925 | Hypoxia-Ischemia, Brain |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D002545 | Brain Ischemia |
| D002561 | Cerebrovascular Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Infection rates in ECMO-patients |
| 1 month |
| 3 months to 12 years |
| Mental Fatigue Scale | Assess fatigue 0-42 points. Higher is worse | 3 months to 12 years |
| modified Rankin Scale | physical function from 0-6 where 0 is best | 3 months to 12 years |
| Actual physical activity | Days per seven days with more than 30 minutes of physical activity | 3 months to 12 years |
| 1-7 years |
| Trailmaking test | Assessmenty of cognitive function. Shorter time is better. | 1-7 years |
| New York heart association class (NYHA class) | Assessment of physical function.1-4, where 1 is best | 1-7 years |
| Euro-Qualy-5D-5L | Quality of life assessment, higher is better. Swedish value set -0.33 - 1.00 | 3 moths to 12 years |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D002534 | Hypoxia, Brain |
| D014652 | Vascular Diseases |
| D000860 | Hypoxia |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |